These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ceftazidime vs. tobramycin for serious infections in urological patients.
    Author: Tammela T, Kontturi M, Usenius R, Uusi-Penttilä S, Viitanen J, Jauhiainen K.
    Journal: J Hosp Infect; 1990 Apr; 15 Suppl A():69-76. PubMed ID: 1971649.
    Abstract:
    A prospective, randomized study was undertaken to compare the efficacy and safety of tobramycin and ceftazidime in the treatment of serious infections in 77 urological patients. Of the 39 tobramycin-treated and 38 ceftazidime-treated patients, 74% and 82%, respectively, were cured clinically. Microbiological cure rates were 72% and 79%, respectively. Three patients treated with tobramycin and two treated with ceftazidime developed a significant superinfection. Both drugs were tolerated well. Because of potential ototoxicity and nephrotoxicity the use of aminoglycosides is less advantageous than ceftazidime for seriously infected urological patients.
    [Abstract] [Full Text] [Related] [New Search]